JP2010530245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530245A5 JP2010530245A5 JP2010513254A JP2010513254A JP2010530245A5 JP 2010530245 A5 JP2010530245 A5 JP 2010530245A5 JP 2010513254 A JP2010513254 A JP 2010513254A JP 2010513254 A JP2010513254 A JP 2010513254A JP 2010530245 A5 JP2010530245 A5 JP 2010530245A5
- Authority
- JP
- Japan
- Prior art keywords
- alphavirus
- rna molecule
- rna
- protein
- recognition sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710929 Alphavirus Species 0.000 claims description 90
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 80
- 101710172711 Structural protein Proteins 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 26
- 230000010076 replication Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 108090000565 Capsid Proteins Proteins 0.000 claims description 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 6
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 6
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims description 6
- 108091081024 Start codon Proteins 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 3
- 101800000120 Host translation inhibitor nsp1 Proteins 0.000 claims description 2
- 108020005350 Initiator Codon Proteins 0.000 claims description 2
- 101710128560 Initiator protein NS1 Proteins 0.000 claims description 2
- 101710144127 Non-structural protein 1 Proteins 0.000 claims description 2
- 101800000512 Non-structural protein 1 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663707P | 2007-06-21 | 2007-06-21 | |
| US60/936,637 | 2007-06-21 | ||
| PCT/US2008/007701 WO2008156829A2 (en) | 2007-06-21 | 2008-06-20 | Promoterless cassettes for expression of alphavirus structural proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014167257A Division JP5995926B2 (ja) | 2007-06-21 | 2014-08-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530245A JP2010530245A (ja) | 2010-09-09 |
| JP2010530245A5 true JP2010530245A5 (enExample) | 2012-06-21 |
| JP5602624B2 JP5602624B2 (ja) | 2014-10-08 |
Family
ID=40156867
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513254A Active JP5602624B2 (ja) | 2007-06-21 | 2008-06-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| JP2014167257A Active JP5995926B2 (ja) | 2007-06-21 | 2014-08-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| JP2016162382A Withdrawn JP2016198114A (ja) | 2007-06-21 | 2016-08-23 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014167257A Active JP5995926B2 (ja) | 2007-06-21 | 2014-08-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| JP2016162382A Withdrawn JP2016198114A (ja) | 2007-06-21 | 2016-08-23 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7850977B2 (enExample) |
| EP (2) | EP2947149B1 (enExample) |
| JP (3) | JP5602624B2 (enExample) |
| CN (1) | CN101802199B (enExample) |
| AU (1) | AU2008266807B2 (enExample) |
| CA (1) | CA2689588C (enExample) |
| DK (2) | DK2947149T3 (enExample) |
| ES (2) | ES2670813T3 (enExample) |
| IL (1) | IL202720A (enExample) |
| NZ (1) | NZ582495A (enExample) |
| PL (2) | PL2183368T3 (enExample) |
| WO (1) | WO2008156829A2 (enExample) |
| ZA (1) | ZA200909080B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850977B2 (en) * | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| EP2370584B1 (en) | 2008-12-01 | 2014-11-05 | Alphavax, Inc. | Use of microRNAs to control virus helper nucleic acids |
| AU2010234362B2 (en) | 2009-04-08 | 2015-11-26 | Alphavax, Inc. | Alphavirus replicon particles expressing TRP2 |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| RS63315B1 (sr) | 2010-08-31 | 2022-07-29 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
| CA2814386C (en) * | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| WO2015118146A1 (en) | 2014-02-10 | 2015-08-13 | Univercells Nv | System, apparatus and method for biomolecules production |
| US12109274B2 (en) | 2015-09-17 | 2024-10-08 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
| AU2017207744A1 (en) | 2016-01-11 | 2018-07-26 | Verndari, Inc. | Microneedle compositions and methods of using same |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| AU2017347725B2 (en) * | 2016-10-17 | 2024-01-04 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
| EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| WO2019053012A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS |
| EP3681904A1 (en) * | 2017-09-13 | 2020-07-22 | Biontech Cell&Gene Therapies GmbH | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
| US11167027B2 (en) | 2017-11-06 | 2021-11-09 | Intervet Inc. | Multivalent feline vaccine |
| CA3080427A1 (en) | 2017-11-06 | 2019-05-09 | Intervet International B.V. | Feline leukemia virus vaccine |
| WO2019110213A1 (en) | 2017-12-08 | 2019-06-13 | Intervet International B.V. | Feline calicivirus vaccine |
| EP3706791A1 (en) | 2017-11-06 | 2020-09-16 | Intervet International B.V. | Rabies virus vaccine |
| EP3706789A1 (en) | 2017-11-06 | 2020-09-16 | Intervet International B.V. | Feline calicivirus vaccine |
| JP2021505560A (ja) | 2017-12-04 | 2021-02-18 | インターベット インターナショナル ベー． フェー． | イヌライム病ワクチン |
| BR112020011044A2 (pt) | 2017-12-04 | 2020-11-17 | Intervet International B.V. | vacinação com partículas de replicon e adjuvante de óleo |
| AU2018383915B9 (en) | 2017-12-15 | 2023-06-01 | Intervet International B.V. | Multivalent feline vaccine |
| CN118976103A (zh) | 2017-12-18 | 2024-11-19 | 英特维特国际股份有限公司 | 猪甲型流感病毒疫苗 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| EP3728611A4 (en) | 2017-12-20 | 2021-09-08 | VLP Therapeutics, Inc. | ALPHAVIRUS REPLICON PARTICLE |
| JP7494117B2 (ja) | 2018-01-19 | 2024-06-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えレプリコン系を使用する免疫応答の誘導および増強 |
| AU2019359204B2 (en) | 2018-10-08 | 2024-12-05 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| JP7513614B2 (ja) | 2018-12-20 | 2024-07-09 | インターベット インターナショナル ベー． フェー． | プライム－ブーストワクチン接種レジメン |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| AU2021233816A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| JP7644993B2 (ja) | 2020-04-17 | 2025-03-13 | ブイエルピー・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン |
| IL297564A (en) | 2020-04-30 | 2022-12-01 | Vlp Therapeutics Inc | Cytokine immunotherapy |
| WO2021228731A1 (en) | 2020-05-11 | 2021-11-18 | Intervet International B.V. | Feline severe acute respiratory syndrome coronavirus 2 vaccine |
| CN115768472A (zh) * | 2020-06-19 | 2023-03-07 | 英特维特国际股份有限公司 | 包含具有特定基因顺序的核酸构建体的甲型猪流感病毒疫苗 |
| EP4168044A1 (en) | 2020-06-19 | 2023-04-26 | Intervet International B.V. | Swine influenza a virus vaccine comprising two distinct rna replicon particles |
| WO2021255221A1 (en) | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages |
| JP7754855B2 (ja) | 2020-06-19 | 2025-10-15 | インターベット インターナショナル ベー． フェー． | ウイルスの別々のノイラミニダーゼ抗原をエンコードする第１、第２および第３の核酸配列を含む核酸構築物を含むブタインフルエンザａウイルスワクチン |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
| US20240024456A1 (en) | 2020-09-07 | 2024-01-25 | Intervet Inc. | Ha stem vaccine for ha antibody-positive targets |
| JP2023549787A (ja) | 2020-11-12 | 2023-11-29 | インターベット インターナショナル ベー． フェー． | キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用 |
| CN118139640A (zh) | 2021-10-25 | 2024-06-04 | 英特维特国际股份有限公司 | 保护仔猪抵抗甲型猪流感病毒感染的疫苗 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) * | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| NZ225583A (en) * | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
| US5217879A (en) * | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| US6770283B1 (en) * | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
| SE9003978D0 (sv) * | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| AU6172194A (en) * | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
| US20020102273A1 (en) | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
| RU2057377C1 (ru) | 1993-08-23 | 1996-03-27 | Уральский электрохимический комбинат | Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5703057A (en) * | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US5639650A (en) | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6197879B1 (en) * | 1995-10-31 | 2001-03-06 | Henkel Corporation | Methods of preparing inorganic pigment dispersions |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| WO1997040165A1 (en) | 1996-04-23 | 1997-10-30 | The Wistar Institute Of Anatomy And Biology | Novel human cytomegalovirus dna constructs and uses therefor |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
| JP2965908B2 (ja) | 1996-07-05 | 1999-10-18 | 株式会社精工技研 | 調温液体シール手段を備える光ディスク成形用金型装置 |
| US5827658A (en) * | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| US5726022A (en) * | 1996-11-18 | 1998-03-10 | Lifespan Biosciences, Inc. | Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences |
| AU732703B2 (en) * | 1996-11-20 | 2001-04-26 | Crucell Holland B.V. | An improved method for the production and purification of adenoviral vectors |
| FR2757169B1 (fr) * | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin |
| US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| US5958738A (en) * | 1997-03-24 | 1999-09-28 | Roche Diagnostics Corporation | Procedure for subtractive hybridization and difference analysis |
| US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
| GB9716611D0 (en) | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
| AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
| GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| FI106618B (fi) | 1998-03-30 | 2001-03-15 | Sandvik Tamrock Oy | Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä |
| WO1999051263A2 (en) | 1998-04-08 | 1999-10-14 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
| US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
| US6146874A (en) * | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| US7267823B2 (en) | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
| WO2000000616A2 (en) | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| ATE382693T1 (de) * | 1998-07-10 | 2008-01-15 | U S Army Medical Res Inst Of I | Impfstoffe gegen neurotoxine von clostridium botulinum |
| AU758019B2 (en) * | 1998-07-10 | 2003-03-13 | U.S. Medical Research Institute Of Infectious Diseases | Anthrax vaccine |
| US6770479B1 (en) * | 1998-07-10 | 2004-08-03 | The United States Of America As Represented By The Secretary Of The Army | Anthrax vaccine |
| AU6289699A (en) * | 1998-10-05 | 2000-04-26 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
| US6329201B1 (en) * | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| WO2000039318A1 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| CA2760534A1 (en) | 1999-04-14 | 2000-10-19 | Novartis Vaccines And Diagnostics, Inc. | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| CA2383519A1 (en) | 1999-08-31 | 2001-03-08 | The University Of North Carolina At Chapel Hill | Antibody dependent enhancement (ade) of alphavirus infection |
| CA2385823A1 (en) * | 1999-10-01 | 2001-04-12 | Haifeng Chen | Production of recombinant aav using adenovirus comprising aav rep/cap genes |
| US7115391B1 (en) * | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| DE60135983D1 (de) | 2000-05-31 | 2008-11-13 | Novartis Vaccines & Diagnostic | Verfahren zur reinigung von alphaviralen replikon partikeln |
| WO2002003917A2 (en) | 2000-07-07 | 2002-01-17 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
| US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| AU2002227506A1 (en) | 2000-07-28 | 2002-02-13 | Visteon Global Technologies, Inc. | An air intake arrangement for an internal combustion engine |
| EP1326990B1 (en) * | 2000-08-29 | 2007-09-19 | Wyeth Holdings Corporation | Packaging of positive-strand rna virus replicon particles |
| WO2002020721A2 (en) | 2000-09-07 | 2002-03-14 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
| DE10049587A1 (de) * | 2000-10-06 | 2002-05-02 | Icon Genetics Ag | Vektorsystem für Pflanzen |
| DE10061150A1 (de) * | 2000-12-08 | 2002-06-13 | Icon Genetics Ag | Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen |
| US6800289B2 (en) * | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
| AU2002305914A1 (en) * | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
| DE10121283B4 (de) | 2001-04-30 | 2011-08-11 | Icon Genetics GmbH, 80333 | Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| DE10143238A1 (de) * | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente |
| DE10143237A1 (de) * | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
| DE60233061D1 (de) | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
| WO2003083065A2 (en) | 2002-03-25 | 2003-10-09 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
| JP3857195B2 (ja) | 2002-07-09 | 2006-12-13 | 株式会社東芝 | 距離継電装置 |
| WO2004043399A2 (en) * | 2002-11-13 | 2004-05-27 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| CA2509979C (en) | 2002-12-13 | 2013-02-26 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| AU2003297039B2 (en) * | 2002-12-13 | 2009-03-05 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| KR101518309B1 (ko) | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| US20060099587A1 (en) * | 2003-06-20 | 2006-05-11 | Johnston Robert E | Alphavirus vectors having attentuated virion structural proteins |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| EP1687033A4 (en) * | 2003-11-12 | 2008-06-11 | Us Navy | IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE |
| US7078087B2 (en) * | 2003-12-31 | 2006-07-18 | Kimberly-Clark Worldwide, Inc. | Wipes with an edge treatment along a leading edge portion |
| US20050266550A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
| WO2006085983A2 (en) | 2004-07-09 | 2006-08-17 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| AU2006302794B2 (en) * | 2005-02-15 | 2011-08-04 | Children's Hospital, Inc. | New live virus vaccines |
| WO2008033966A2 (en) * | 2006-09-12 | 2008-03-20 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| US7850977B2 (en) | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| KR101668849B1 (ko) * | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
-
2008
- 2008-06-20 US US12/143,320 patent/US7850977B2/en active Active
- 2008-06-20 DK DK15173487.8T patent/DK2947149T3/en active
- 2008-06-20 DK DK08825920.5T patent/DK2183368T3/en active
- 2008-06-20 WO PCT/US2008/007701 patent/WO2008156829A2/en not_active Ceased
- 2008-06-20 ES ES15173487.8T patent/ES2670813T3/es active Active
- 2008-06-20 CN CN2008801036605A patent/CN101802199B/zh active Active
- 2008-06-20 PL PL08825920.5T patent/PL2183368T3/pl unknown
- 2008-06-20 US US12/665,497 patent/US8460913B2/en active Active
- 2008-06-20 AU AU2008266807A patent/AU2008266807B2/en active Active
- 2008-06-20 EP EP15173487.8A patent/EP2947149B1/en active Active
- 2008-06-20 EP EP08825920.5A patent/EP2183368B1/en active Active
- 2008-06-20 PL PL15173487T patent/PL2947149T3/pl unknown
- 2008-06-20 CA CA2689588A patent/CA2689588C/en active Active
- 2008-06-20 NZ NZ582495A patent/NZ582495A/en unknown
- 2008-06-20 JP JP2010513254A patent/JP5602624B2/ja active Active
- 2008-06-20 ES ES08825920.5T patent/ES2588906T3/es active Active
-
2009
- 2009-12-14 IL IL202720A patent/IL202720A/en active IP Right Grant
- 2009-12-18 ZA ZA200909080A patent/ZA200909080B/xx unknown
-
2014
- 2014-08-20 JP JP2014167257A patent/JP5995926B2/ja active Active
-
2016
- 2016-08-23 JP JP2016162382A patent/JP2016198114A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530245A5 (enExample) | ||
| Rauch et al. | New vaccine technologies to combat outbreak situations | |
| Rayner et al. | Alphavirus vectors and vaccination | |
| Anraku et al. | Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity | |
| Schlesinger | Alphaviruses—vectors for the expression of heterologous genes | |
| Curtis et al. | Heterologous gene expression from transmissible gastroenteritis virus replicon particles | |
| Emonet et al. | Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies | |
| Gorchakov et al. | Selection of functional 5′ cis-acting elements promoting efficient Sindbis virus genome replication | |
| JP2015527296A5 (enExample) | ||
| JP2015522581A5 (enExample) | ||
| Atasheva et al. | Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation | |
| CN103088049A (zh) | 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用 | |
| WO2023035372A1 (zh) | 一种有限自我复制mRNA分子系统、制备方法及应用 | |
| EP3158059B1 (en) | Method for rapid generation of an attenuated rna virus | |
| JP2025169275A5 (enExample) | ||
| Conradie et al. | Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus | |
| Ren et al. | Recent advances in Bunyavirus reverse genetics research: systems development, applications, and future perspectives | |
| Pereira-Gómez et al. | Altering compositional properties of viral genomes to design live-attenuated vaccines | |
| US10407667B2 (en) | Method for rapid generation of an infectious RNA virus | |
| Hewson | RNA viruses: emerging vectors for vaccination and gene therapy | |
| Casmil et al. | Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen | |
| CN118086288A (zh) | 多顺反子的自放大rna及制备方法 | |
| Lundstrom | Self-replicating RNA viral vectors in vaccine development and gene therapy | |
| CN115725657A (zh) | 一种节段化的水泡性口炎病毒载体及其制备方法和应用 | |
| CN101914566B (zh) | 基于E2基因的可插入式猪瘟病毒cDNA载体构建及应用 |